FDA expands pirtobrutinib into first-line CLL/SLL for adults without 17p deletion, delivering major PFS gains versus bendamustine-rituximab.
|Videos|June 11, 2019
Recurrent Cutaneous Squamous Cell Carcinoma
Recurrent Cutaneous Squamous Cell Carcinoma
Advertisement
Case: A 74-Year-Old Male With Recurrent Metastatic CSCC
November 2017
- A 74-year-old male from Florida, with history of multiple resections of CSCC on neck, back and shoulders presents with new deep lesion that exhibited perineural invasion and c/o palpable left axillary mass
- Imaging confirmed 6cm left axillary nodal conglomerate
- Patient treated with neoadjuvant cisplatin/5FU for 3 cycles
- Surgical resection of primary lesion; Lymphadenectomy revealed CSCC involvement in 12 out of 16 resected lymph nodes
May 2018
- Follow-up scans revealed early disease progression with multiple pulmonary nodules
- Patient started on carboplatin/paclitaxel for 3 cycles
November 2018
- Repeat imaging showed disease progression in pulmonary nodules and multiple lymphadenopathies; mediastinal, left and right axillary; bone metastases
- Patient started on cemiplimab for 3 cycles
February 2019
- Reimaging PET-CT revealed reduction in size and metabolic activity of right and left axillary, and mediastinal lymphadenopathies; pulmonary nodules had considerable reduction in size and were no longer substantial
Advertisement
Related to this article
Submission of a new drug application for zipalertinib plus chemotherapy has begun under the FDA's RTOR program, based on phase 3 REZILIENT3 data showing a 6-month PFS gain.
Insurance hurdles and steep out-of-pocket costs often delay or prevent patients from filling specialty oral blood cancer drugs, even after eventual approvals.
Telehealth transplant consults help patients with multiple myeloma overcome racial, age, and rural barriers, speeding eligibility screening and expanding access to specialists.
The MUC16xCD3 bispecific antibody showed a 73% response rate in phase 1/2 trial; the sponsor announced plans for a potential registrational cohort and phase 3 trial.
Five myeloma experts share their top takeaways from IMS 2026, including the CERVINO trial and long-term follow-up from the PERSEUS study.
Giredestrant plus everolimus reduced the risk of progression or death by 44% in the ITT population and 62% in ESR1-mutated disease in phase 3 evERA data published in NEJM.
The oral azacitidine/cedazuridine combination was compared with subcutaneous azacitidine in the phase 3 portion of the AZTOUND trial.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Ubamatamab Shows Durable Responses in Low-Grade Serous Ovarian Cancer
2
What Stood Out at IMS 2026? Five Myeloma Experts Weigh In
3
Giredestrant Plus Everolimus Improves PFS in ER+ Advanced Breast Cancer
4
New Drug Application Filed for Savolitinib/Osimertinib in MET+ NSCLC
5